Indonesia and China Will Sign New Drug Safety Pact
The agreement will replace an expired regulatory framework and facilitate vaccine technology transfer.
Updated on Sept. 20, 2026 in Biotech
Live Poll
Do you believe international government partnerships improve the safety of imported food and drugs?
Indonesia and China will sign a new memorandum of understanding on food and drug safety during an upcoming APEC high-level meeting. This agreement follows the expiration of the previous partnership in June 2024.
Why it matters
The partnership aims to strengthen drug safety standards and facilitate technology exchanges, specifically targeting vaccine production and manufacturing certification. It marks a formal renewal of cooperation between the Indonesian Food and Drug Authority and China's National Medical Products Administration.
The partnership relies on a mutual recognition framework where both the Indonesian Food and Drug Authority, a World Health Organization-Listed Authority, and China's National Medical Products Administration perform secondary assessments of data evaluated by established regulators.
The players
Prabowo Subianto
The President of Indonesia, overseeing the nation's regulatory and diplomatic efforts regarding health infrastructure.
Xi Jinping
The President of China, coordinating international technology and trade partnerships.
Indonesian Food and Drug Authority
A national regulatory body and World Health Organization-Listed Authority responsible for the safety and efficacy of medicinal products.
National Medical Products Administration
China's central agency tasked with the regulation of drugs, medical devices, and cosmetics.
Taruna Ikrar
A representative who has focused on the integration of artificial intelligence in Advanced Therapy Medicinal Products.
The details
The agreement focuses on regulatory frameworks, investment, safety, quality, and efficacy of pharmaceuticals. As part of this collaboration, Chinese pharmaceutical companies are expected to pursue good manufacturing practice (GMP) certification—a standard ensuring products are consistently produced and controlled according to quality standards—from Indonesian regulators. The partnership also includes specialized initiatives, such as research into artificial intelligence applications for Advanced Therapy Medicinal Products—biopharmaceuticals derived from genes, tissues, or cells.
Timeline
The previous memorandum of understanding between the two agencies expired in June 2024.
The signing of the new agreement is scheduled for the upcoming APEC high-level meeting.
The Tech Race
The agreement functions as an extension of the World Health Organization-Listed Authority framework to harmonize safety protocols. It prioritizes the cross-border validation of clinical and manufacturing data to accelerate the regional deployment of advanced medicinal products.
This agreement will likely streamline the approval process for imported medical products and vaccines for patients across Indonesia. It provides a clearer pathway for local production through Chinese pharmaceutical technology investment once certification standards are met.
The takeaway
This pact signals a major consolidation of vaccine manufacturing standards between two of the world's largest pharmaceutical markets. Watch for the specific list of Chinese firms that receive Indonesian good manufacturing practice certification following the APEC meeting.
Further reading
For more on international regulatory collaboration and health infrastructure, visit Biotech.
Live Poll
Do you believe international government partnerships improve the safety of imported food and drugs?
